103,900 Shares in LivaNova PLC (NASDAQ:LIVN) Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 103,900 shares of the company's stock, valued at approximately $4,812,000. Jefferies Financial Group Inc. owned approximately 0.19% of LivaNova at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. KBC Group NV boosted its holdings in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after purchasing an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares during the last quarter. Rhumbline Advisers boosted its holdings in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after purchasing an additional 899 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in LivaNova during the fourth quarter worth about $2,772,000. Finally, Envestnet Asset Management Inc. boosted its holdings in LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after purchasing an additional 5,850 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on LIVN shares. Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Barclays dropped their target price on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus dropped their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Finally, Wolfe Research lowered shares of LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $59.17.

LivaNova Price Performance

NASDAQ:LIVN traded up $0.58 during trading hours on Friday, hitting $44.40. 517,238 shares of the stock traded hands, compared to its average volume of 646,354. The company has a market cap of $2.42 billion, a price-to-earnings ratio of 105.71 and a beta of 0.84. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $62.04. The stock has a 50 day moving average price of $38.39 and a 200 day moving average price of $44.81.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.